Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026

Novo Nordisk reported real-world observational data in adults with MASH: semaglutide 2.4 mg was associated with an adjusted mean 18.9 lb weight reduction at six months versus 5.6 lb with resmetirom, and greater reductions in AST and HbA1c. In a separate 12-month analysis, semaglutide initiators had a 30.7 lb weight reduction versus 2.4 lb among non-initiators, alongside greater liver-enzyme reductions. Both studies were retrospective and nonrandomized, so the findings show associations and cannot establish causality.

Analysis

The investable signal is commercial positioning, not proof of superior liver-disease modification. If clinicians treat obesity, diabetes and MASH together, semaglutide’s broad metabolic effects could make it the default first step and expand Novo Nordisk’s persistence and prescriber advantage. But the observational comparison cannot separate drug effect from weight loss, treatment selection or follow-up bias; enzyme changes are not equivalent to demonstrated fibrosis or clinical-outcome benefit. That limits how much this should change long-run earnings expectations on its own.

Resmetirom should not be treated as displaced: its stronger LDL reduction in the comparison may preserve a role for patients where lipid management is central, or support combination/sequenced treatment. The key competitive question is whether real-world use creates a larger treated funnel for GLP-1s or merely shifts existing MASH patients between therapies. Eli Lilly’s competing incretin franchise is a sector spillover, though this release does not establish an advantage for Novo versus Lilly.

Near term, the company-sponsored conference data are a modest sentiment tailwind, not a durable catalyst. Over 1–3 months, watch persistence, payer access and independent replication; over 6–18 months, the pivotal confirmatory evidence and regulatory verification matter more than retrospective enzyme data. A downside path is that real-world tolerability, access constraints or confirmatory results fail to convert metabolic improvement into liver benefit. No standalone valuation or price target is supportable from the supplied information.

Key Decisions for Investors

• Do not chase NVO solely on this release. Treat it as a modest positive to the commercial narrative, with position sizing contingent on valuation and existing exposure.
• Watch for independent confirmation and treatment-persistence data, plus payer coverage and refill trends. If these improve, reassess the durability of NVO’s MASH uptake; if uptake is driven mainly by weight-loss prescribing without MASH-specific evidence, discount the indication-specific revenue case.
• Track the confirmatory trial/regulatory path as the key 6–18 month catalyst. Failure to verify clinical benefit, or evidence that liver outcomes do not improve beyond enzyme changes, would falsify the structural bullish thesis.
• Do not assume resmetirom loses share: monitor treatment sequencing and combination use, and whether its LDL effect preserves a distinct patient segment. The comparative study is observational and does not establish a head-to-head clinical-outcome advantage.